Workflow
Tigermed(300347)
icon
Search documents
泰格医药(300347) - 2020 Q3 - 季度财报
2020-10-29 16:00
Financial Performance - Operating revenue for the quarter was CNY 848.47 million, a growth of 22.31% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 319.21 million, reflecting an increase of 81.37% year-on-year[3] - Basic earnings per share rose to CNY 0.3887, a 63.59% increase compared to the same quarter last year[3] - The company reported a net profit of CNY 2.87 billion, up from CNY 1.80 billion, an increase of 59.9% year-over-year[91] - The total operating revenue for Q3 2020 reached ¥848,471,965.16, an increase of 22.4% compared to ¥693,703,343.54 in the same period last year[34] - Net profit for Q3 2020 was ¥367,056,987.95, compared to ¥198,990,793.97 in Q3 2019, representing an increase of 84.7%[36] - The company's net profit for Q3 2020 reached CNY 1,402,984,242.09, a significant increase from CNY 577,187,118.63 in the same period last year, representing a growth of approximately 143.5%[43] Assets and Liabilities - Total assets reached CNY 18.83 billion, an increase of 149.97% compared to the previous year[3] - The company's total assets amounted to CNY 18.83 billion, a significant increase from CNY 7.53 billion at the end of 2019[30] - The total liabilities of the company were CNY 1.30 billion, down from CNY 2.01 billion, representing a reduction of approximately 35.3%[29] - The total liabilities of the company were ¥1,063,124,590.00, down from ¥1,390,656,889.07 in the previous year, indicating a decrease of 23.5%[33] - The company's total current liabilities amounted to CNY 899.52 million, down from CNY 1.79 billion, a decrease of 50.2%[90] Cash Flow - Cash flow from operating activities reached CNY 297.30 million, up 38.77% year-on-year[3] - The net cash flow from operating activities increased by 51.92% from CNY 340,296,720.39 to CNY 516,982,759.61, driven by higher project revenues and improved collection[17] - The net cash flow from financing activities increased by 624.73% from CNY 1,324,800,338.44 to CNY 9,601,255,839.27, largely due to funds raised from the company's listing[17] - The net cash flow from operating activities for Q3 2020 was CNY 516,982,759.61, an increase of 52% compared to CNY 340,296,720.39 in Q3 2019[49] - Total cash inflow from operating activities reached CNY 2,301,161,182.22, up from CNY 1,931,055,410.09 in the same period last year[49] Shareholder Information - The total number of shareholders at the end of the reporting period was 39,309[8] - The largest shareholder, Ye Xiaoping, holds 20.31% of the shares, totaling 177,239,541 shares[8] - The company has completed a share buyback of 7,005,832 shares, representing 1.40% of the total share capital, with a total transaction amount of approximately 310 million RMB[21] - The total number of ordinary shareholders at the end of the reporting period was 39,309, with the top three shareholders holding 20.31%, 14.11%, and 13.86% respectively[69] Investments and Acquisitions - The company plans to invest 600 million RMB in Suzhou Taifu Huai Jin Venture Capital Partnership, indicating a strategic move for market expansion[20] - The company reported a total investment income of approximately ¥67.75 million from newly added subsidiaries during the reporting period[68] - The company reported a profit from the disposal of non-current financial assets amounting to approximately ¥945.19 million, primarily due to gains from fair value changes[68] Financial Ratios and Indicators - The weighted average return on equity was 2.68%, a decrease of 2.16% compared to the previous year[64] - The company’s financial indicators showed significant changes, with a focus on capital structure and debt levels[74] - The company reported a total comprehensive income of CNY 256,588,815.57 for the quarter, compared to CNY 228,284,253.22 in the previous year[99] Research and Development - Research and development expenses for Q3 2020 were ¥38,351,781.24, up from ¥30,887,652.91, reflecting a year-over-year increase of 24.1%[35] - The company's research and development expenses for the quarter were CNY 36,180,803.89, compared to CNY 32,541,492.63 in the same period last year, reflecting an increase of approximately 11.9%[46] Regulatory Compliance and Governance - The company has committed to not providing financial assistance to stock incentive plan participants, ensuring compliance with regulations[23] - The company has not disclosed any performance forecasts for the upcoming reporting period[24] - The company has not encountered any overdue commitments during the reporting period[85]